🧬 Research Summary | Discovery of a New Weakness in Stem Cells That Cause High-Risk Leukemia
A research team at the University of Colorado Anschutz has uncovered a unique biological weakness in the stem cells responsible for high-risk myelodysplastic syndromes (Myelodysplastic Syndromes – MDS), a highly aggressive blood cancer condition that can progress to acute myeloid leukemia (AML). The study focuses on these cells’ excessive dependence on the vital molecule NAD (Nicotinamide Adenine Dinucleotide), which is necessary for cellular energy production, offering an opportunity to target them precisely while leaving healthy cells less affected.
🩺 What Are Myelodysplastic Syndromes (MDS)?
Myelodysplastic syndromes are cancerous diseases that affect the bone marrow’s ability to produce healthy blood cells that perform vital functions such as oxygen transport, blood clotting, and resistance to infections. Patients with MDS face symptoms such as severe anemia, recurrent infections, and a constant need for blood transfusions. High-risk versions of the disease can also progress to acute myeloid leukemia (AML), which is difficult to treat.
Most people with MDS are diagnosed at older ages, with between 10,000 to 20,000 diagnoses annually in the United States alone.
🧠 Abnormal Dependence of Disease-Causing Stem Cells on Energy
Stem cells play a fundamental role in the formation of normal blood cells, but when they turn into cancer cells as in high-risk MDS, they lose their ability to produce healthy blood cells and instead generate nonfunctional cells that contribute to worsening the disease.
The researchers focused on comparing the biological differences between healthy and cancerous stem cells. Experiments showed that MDS cells rely heavily on a specific metabolic pathway known as the “NAD salvage pathway,” which recycles NAD to maintain sufficient levels inside cells.
An enzyme called nicotinamide phosphoribosyltransferase (NAMPT) emerged as a potential target for treating this type of cancer, because cancer cells depend on it much more deeply than healthy cells do.
🌱 “Energy addiction” in cancer stem cells
The researchers described MDS cells’ dependence on NAD as similar to energy addiction. Normal cells are able to adapt through other shifts in energy production when environmental or physical conditions change. In contrast, MDS cells lack this flexibility and rely entirely on this specific pathway to produce energy.
When the NAMPT enzyme was disabled, NAD levels inside these cells decreased, leading to an “energy crisis” that selectively weakened the disease-causing cancer cells, while healthy cells were able to adjust their energy-supplying mechanisms to compensate for the deficit.
🧪 Future steps toward more precise and effective treatments
The experiments relied on MDS cells taken from patients and animal models to show the success of disrupting NAD in reducing the number of stem cells responsible for disease progression.
Next on the research path is the clinical study of drugs that target the NAMPT enzyme and the evaluation of their potential to improve treatment for MDS and related blood cancers.
Dr. Eric M. Pietras, one of the study leaders, says: “Our focus is on developing treatments that exploit the biological differences between normal cells and cancer cells, which could lead to more precise and more effective therapies.”
🧬 Why do MDS cells depend on NAD?
- NAD is a vital molecule that plays an essential role in metabolism and energy production in cells.
- MDS cells consume NAD at a much higher rate than healthy cells, which causes them to develop an “excessive dependence” on the NAD salvage pathway.
- The NAMPT enzyme acts in this pathway as a key element in recycling NAD and maintaining its levels.
🧠 How can this information be used for better treatment?
- By disabling NAMPT, NAD levels are reduced, causing an energy crisis for cancer cells.
- Normal cells have the ability to alter other metabolic pathways to compensate for the energy shortfall, so they are affected less.
- Drugs that target this pathway can precisely attack the disease-causing cells while reducing damage and losses in healthy cells.
🌟 Conclusion
The discovery of this weakness in high-risk MDS cancer stem cells represents a promising window into a new understanding that makes it possible to develop more precise treatments. Excessive dependence on NAD and the NAD salvage pathway provides a clear therapeutic target that can multiply treatment effectiveness and lessen side effects. These discoveries pave the way for clinical treatment stages focused on inhibiting the NAMPT enzyme, forming a new ray of hope for hundreds of thousands of patients suffering from serious blood cancers.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
